Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease
- 26 April 2011
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 33 (12) , 1261-1272
Abstract
Patients with inflammatory bowel disease (IBD) are at increased risk of osteoporosis. A number of studies have emerged in recent years indicating that tumour necrosis factor (TNF) blockade appears to have a beneficial effect on bone mineral density (BMD) in IBD patients. To provide a review of the available data regarding the effect of the currently licensed anti-TNF-α therapies on bone metabolism and BMD in IBD patients. A Medline search was performed using the search terms 'infliximab', 'bone metabolism', 'IBD', 'BMD', 'bone markers', 'adalimumab', 'bone disease', 'Crohn's disease' and 'ulcerative colitis'. Infliximab has a beneficial effect on bone turnover markers in Crohn's disease (CD) patients in the short term. The longest study to date comprising 24 CD patients showed an overall improvement in two bone formation markers - b-alkaline phosphatase (P = 0.022) and osteocalcin (P = 0.008) at 4 months post-treatment. Moreover, the largest study to date comprising 71 CD patients showed significant improvement in sCTx, a bone resorption marker (P = 0.04) at week-8 post-treatment. There is little data looking at the effect of anti-TNF-α therapy on bone metabolism in ulcerative colitis. Moreover, the long-term effects of anti-TNF-α therapy on bone structure and fracture risk in IBD patients are currently not known. The effect of cessation of anti-TNF-α therapy on bone metabolism is also unknown. Properly controlled long-term trials are needed to fully evaluate the impact of TNF blockade on bone mineral density.Keywords
This publication has 69 references indexed in Scilit:
- Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone lossAnnals of the Rheumatic Diseases, 2009
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Tumor necrosis factor‐α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism†Journal of Cellular Biochemistry, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and CytokinesBiochemical and Biophysical Research Communications, 1998
- Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel diseaseJournal of Internal Medicine, 1996
- A controlled study of bone mineral density in patients with inflammatory bowel disease.Gut, 1995
- Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosisJournal of Bone and Mineral Research, 1995
- Metabolic bone assessment in patients with inflammatory bowel diseaseGastroenterology, 1995
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983